Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2 NSP1 is believed to be a potential drug target. Its C-terminal region which associates with ribosomal subunit has shown good binding with an anticancer drug, Mitoxantrone.
Article activity feed
-
-
SciScore for 10.1101/2021.09.14.460211: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources All the measurements were smoothened by 5 points through the adjacent-averaging method in Origin software. Originsuggested: (Origin, RRID:SCR_014212)OPLS 2005 forcefield in Desmond simulation package (v2018.4) 29 and GROMOS54A7 forcefield, utilizing the in-house cluster facility, simulation of the complex was achieved in Gromacs v5.1.2 30. Gromacssuggested: (GROMACS, RRID:SCR_014565)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit …SciScore for 10.1101/2021.09.14.460211: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources All the measurements were smoothened by 5 points through the adjacent-averaging method in Origin software. Originsuggested: (Origin, RRID:SCR_014212)OPLS 2005 forcefield in Desmond simulation package (v2018.4) 29 and GROMOS54A7 forcefield, utilizing the in-house cluster facility, simulation of the complex was achieved in Gromacs v5.1.2 30. Gromacssuggested: (GROMACS, RRID:SCR_014565)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
